FDA approves sNDA for pediatric autism drug ABILIFY

20. November 2009 23:40

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. [More]

eb34af81-8141-4574-b270-52cb5d01cd03|0|.0

Posted in: Child Health News | Pharmaceutical News

Tags: Abilify, Antidepressant, Antipsychotic, Autism, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, Cell, Cerebrovascular Disease, Constipation, Creatinine, Dehydration, Dementia, Depression, Diabetes, Diabetes Mellitus, Dystonia, Exercise, Heart Failure, Hyperglycemia, Hypersensitivity, Insomnia, Leukopenia, Lipids, Nausea, Neutropenia, New Drug Application, Obesity, Pediatrics, Pneumonia, Psychosis, Schizophrenia, Speech, Stroke, Tardive Dyskinesia, Urticaria, Vomiting

Study reveals effectiveness of radiation therapy in achieving local control and palliation in patients with PNTs

20. November 2009 11:10

Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy, according to a largest of its kind study in the November 15 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO). [More]

f8096562-ef59-445e-8e33-e46d1b1d4f06|0|.0

Posted in: Medical Science News | Medical Condition News

Tags: Cancer, Education, Hematology, Jaundice, Nausea, Oncology, Pancreatic Cancer, Radiation Therapy, Vomiting

High prevalence of asthma among children with H1N1

19. November 2009 22:55

A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu. [More]

a79119cd-2710-45b6-b11f-868707e942ed|0|.0

Posted in: Child Health News | Medical Condition News | Disease/Infection News

Tags: Asthma, Cough, Diarrhea, H1N1, Hospital, Influenza, Pandemic, Vomiting

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

19. November 2009 00:22

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. [More]

9f19f465-9b09-4558-8717-5dc5f9c0f5b8|0|.0

Posted in: Drug Trial News | Pharmaceutical News

Tags: Anorexia, Biopsy, Biotechnology, Cancer, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diarrhea, Erlotinib, Head and Neck Cancer, Hepatocellular Carcinoma, Lung Cancer, Nausea, Non-Small Cell Lung Cancer, Pfizer, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vomiting

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

18. November 2009 07:34

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research. [More]

fca250df-5848-4337-8a95-05b6cd411164|0|.0

Posted in: Pharmaceutical News

Tags: Abstinence, Anxiety, Brain, Cardiovascular Disease, Constipation, Drug Abuse, Morphine, Nausea, Nicotine, Nicotine Addiction, Pfizer, Smoking, Smoking Cessation, Tobacco, Vomiting

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

18. November 2009 06:35

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. [More]

959d26c5-8d38-4083-a198-e232442942a6|0|.0

Posted in: Healthcare News

Tags: Cancer, Chemotherapy, Constipation, Diarrhea, Education, Lung Cancer, Nausea, Oncology, Vomiting

Almost half of the women in the UK suffer from lack of vitamin A, find scientists

18. November 2009 01:23

Almost half of UK women could be suffering from a lack of vitamin A due to a previously undiscovered genetic variation, scientists at Newcastle University have found. [More]

33c314a7-d0d4-4c9a-9573-a5a3a536a293|0|.0

Posted in: Medical Science News | Women's Health News

Tags: Beta-Carotene, Nutrition, Pregnancy, Vitamin A, Vomiting

AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline

17. November 2009 05:02

To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing. [More]

ac48c877-eb35-45fc-9d99-0eb9b9d6de31|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Acetylation, Adenosine, Amino Acid, Anemia, Angiogenesis, Autophagy, Blood Pressure, Breast Cancer, Cancer, Cediranib, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, DNA, Gene Expression, Hematology, Leukemia, Myeloid Leukemia, Nausea, Oncology, Ovarian Cancer, Radiotherapy, Stem Cell, Stress, Vomiting

Genentech submits sBLAs to the FDA for Avastin

17. November 2009 03:36

Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy. [More]

52d6ae04-8005-4377-aa8f-72b645331f28|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

16. November 2009 08:49

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002). [More]

7c593e0c-d5f3-4682-acec-c6479a87a418|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Alcohol Dependence, Analgesia, Biotechnology, Depression, Diabetes, Dyspnea, Headache, Heroin, Hypersensitivity, Insomnia, Nausea, Nervous System, New Drug Application, Opioid Drug, Opioids, Pneumonia, Psychiatry, Schizophrenia, Vivitrol, Vomiting

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

16. November 2009 06:38

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009. [More]

8147ae38-1d8c-4d45-96a1-c99abdbcad4e|0|.0

Posted in: Business / Finance

Tags: Cancer, Chemotherapy, Drug Delivery, Granisetron, Nausea, New Drug Application, Palonosetron, Prescription Drug, Vomiting

Ginger effective in treating post-chemo nausea in cancer patients

16. November 2009 06:04

Reed's, Inc., maker of the top-selling sodas in natural food stores nationwide, announced today that it will be exhibiting at the Chemotherapy Foundation Symposium XXVII New Perspectives in Oncology Practice Seminar, Saturday November 14th, at the Marriott Marquis in New York, NY. [More]

d52ab2d7-6590-4c74-b100-eaed414bb881|0|.0

Posted in: Medical Research News | Medical Condition News

Tags: Cancer, Chemotherapy, Dermatology, Ginger, Morning Sickness, Nausea, Oncology, Vomiting

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

16. November 2009 05:57

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

61ba286d-5b3b-4047-95a2-27f2235034f8|0|.0

Posted in: Child Health News | Drug Trial News

Tags: Abdominal Pain, Arteriosclerosis, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, CDC, Depression, Drug Abuse, Glaucoma, Headache, Hypersensitivity, Hyperthyroidism, Insomnia, Nausea, Psychiatry, Psychosis, Stroke, Vomiting

Shire announces findings from Phase 3 study data with Vyvanse

13. November 2009 04:41

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. [More]

0d7781a0-d746-4dd4-9500-ffd869a3587b|0|.0